An adverse publicity campaign is still being carried out using a section of the media on the alleged fraud pertaining to the oncology drug 'Oncaspar', at the Maharagama National Cancer Institute (NCI), the company disclosed.

An independent three-member independent Committee headed by retired Supreme Court judge, Justice Jayantha Perera appointed by the Court of Appeal exonerated OMACX of any wrongdoing after a lengthy inquiry in 2014.

Certain unsuspecting media institutions are still being used to sling mud by describing OMACX as a "blacklisted company”, a media release issued by the company said.

News clippings are scanned and emailed to principals overseas with the aim of severing links with QMACX, it added.

The Company noted that some competitors have also joined the campaign  to push for the blacklisting of QMACX and effectively shut it out of the Health Ministry tender process for oncology drugs.

OMACX is a key supplier of a range of life-saving oncology products to the Ministry of Health through the Medical Supplies Division (MSD). The Company has been acclaimed as one of the very few industry players in Sri Lanka which has acquired the know-how and skills to market innovative niche molecules.

Marketing complicated molecules is a tough task in the competitive pharmaceuticals Industry, but with its specialized knowledge, OMACX is confident of facing the challenges ahead, the media release said.